NOVAVAX INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
NVAX$10.20-6.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share information)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $530,230 | $568,505 |
| Marketable securities | 392,888 | — |
| Restricted cash | 10,626 | 10,424 |
| Accounts receivable | 108,285 | 297,240 |
| Inventory | 8,749 | 41,696 |
| Prepaid expenses and other current assets | 78,164 | 226,023 |
| Total current assets | 1,128,942 | 1,143,888 |
| Property and equipment, net | 138,413 | 305,771 |
| Right of use asset, net | 161,585 | 185,218 |
| Goodwill | 107,478 | 127,454 |
| Other non-current assets | 24,000 | 35,159 |
| Total assets | $1,560,418 | $1,797,490 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $41,579 | $132,610 |
| Accrued expenses | 211,165 | 394,668 |
| Deferred revenue | 675,067 | 241,310 |
| Current portion of finance lease liabilities | 7,009 | 5,142 |
| Other current liabilities | 219,596 | 861,408 |
| Total current liabilities | 1,154,416 | 1,635,138 |
| Deferred revenue | 446,819 | 622,210 |
| Convertible notes payable | 169,684 | 168,016 |
| Non-current finance lease liabilities | 53,726 | 55,923 |
| Other non-current liabilities | 359,614 | 33,130 |
| Total liabilities | 2,184,259 | 2,514,417 |
| Commitments and contingencies (Note 17) | ||
| Preferred stock, $0.01 par value, 2,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Stockholders’ deficit: | ||
| Common stock, $0.01 par value, 600,000,000 shares authorized at December 31, 2024 and 2023; and 161,942,677 shares issued and 160,421,136 shares outstanding at December 31, 2024 and 140,506,093 shares issued and 139,505,770 shares outstanding at December 31, 2023 | 1,619 | 1,405 |
| Additional paid-in capital | 4,501,403 | 4,192,164 |
| Accumulated deficit | (5,008,450) | (4,820,951) |
| Treasury stock, 1,521,541 shares, cost basis at December 31, 2024 and 1,000,323 shares, cost basis at December 31, 2023 | (95,854) | (92,267) |
| Accumulated other comprehensive income (loss) | (22,559) | 2,722 |
| Total stockholders’ deficit | (623,841) | (716,927) |
| Total liabilities and stockholders’ deficit | $1,560,418 | $1,797,490 |
F- 8
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.